Independent pharmacies face a cash-flow problem the chains can absorb but independents feel sharply: drug inventory — especially expensive brand and specialty medications — must be bought up front, while PBM and insurance reimbursements lag and are clawed back through DIR fees. Margins look thin and volatile even when prescription volume is strong. This guide covers how independent pharmacies fund inventory, the reimbursement gap, and growth.
Why independent pharmacies run cash-tight
Drug inventory is bought before reimbursement arrives, PBM reimbursement spreads and DIR claw-backs make margins look thin and volatile, and much of the value is in inventory and patient files rather than collateral. Banks underwrite slowly and miss the steady prescription revenue underneath.
Funding options for pharmacies
Revenue-based funding (a merchant cash advance) advances a lump sum against your deposits and prescription revenue and is remitted as a small share of revenue — usable to buy drug and specialty inventory, cover payroll through reimbursement lags, upgrade systems, or acquire another pharmacy. The advantage is speed and approval based on deposits rather than credit or collateral.
How approval works
Approval weighs your pharmacy's deposits and prescription revenue, not your credit score or collateral, so a pharmacy with steady scripts can be evaluated despite credit blemishes. Eligible applications can get a same-day decision with funding commonly within 24 to 72 hours. Not all applicants qualify.
The bottom line: pharmacy funding should keep inventory stocked while you wait on reimbursement. Y Millennial Funding is a direct funder of revenue-based funding for independent pharmacies doing $25,000 or more in monthly revenue — a small business loan alternative, not a loan.